GlassScriptPhysician profile
Brenda Simpson
NPI 1750676250
$34,430.29
in general payments reported to CMS, 2019-2025
22 companies · $3,719 in 2025
The $3,719 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,985 · 2020: $11K · 2021: $1,110 · 2022: $406 · 2023: $670 · 2024: $13K · 2025: $3,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,190 · Food and Beverage: $2,530 · Travel and Lodging: $1,423 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,392.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,190.00 |
| Food and Beverage | $2,529.54 |
| Travel and Lodging | $1,422.92 |
| Education | $204.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14,875.12 | 2019-2023 | |
| Incyte Corporation | $9,305.64 | 2022-2024 | Opzelura |
| Genzyme Corporation | $7,571.99 | 2019-2025 | |
| Strata Skin Sciences, INC. | $545.77 | 2022-2025 | Xtrac |
| Alexion Pharmaceuticals, INC. | $450.70 | 2023-2024 | Koselugo |
| Abbvie INC. | $412.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.79 | 2024 | Sotyktu |
| Janssen Biotech, INC. | $230.75 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $143.98 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $122.15 | 2019-2025 | |
| Lilly USA, LLC | $97.92 | 2023 | Olumiant |
| Sun Pharmaceutical Industries INC. | $97.17 | 2022 | |
| Dermavant Sciences, INC. | $78.90 | 2024 | Vtama |
| Krystal Biotech INC | $59.23 | 2023-2025 | Vyjuvek |
| Galderma Laboratories, L.P. | $46.65 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $30.72 | 2025 | Gomekli |
| Leo Pharma INC. | $25.45 | 2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $24.68 | 2025 | Zoryve |
| Amgen INC. | $19.32 | 2023 | Otezla, Enbrel |
| Journey Medical Corporation | $18.18 | 2024 | |
| Organon LLC | $17.17 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $14.65 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.